Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Ankylosing Spondylitis and Undifferentiated Spondyloarthropathy Clinical Presentation

  • Author: Lawrence H Brent, MD; Chief Editor: Herbert S Diamond, MD  more...
 
Updated: Jan 20, 2016
 

History

Key components of the patient history that suggest ankylosing spondylitis (AS) include the following:

  • Insidious onset of low back pain
  • Onset of symptoms before age 40 years
  • Presence of symptoms for more than 3 months
  • Symptoms worse in the morning or with inactivity
  • Improvement of symptoms with exercise [1]

General symptoms

Symptoms of ankylosing spondylitis (AS) include those related to inflammatory back pain, peripheral enthesitis and arthritis, and constitutional and organ-specific extra-articular manifestations. Because ankylosing spondylitis is a systemic inflammatory disease, systemic features are common.

Chronic pain and stiffness are the most common complaints of patients with AS. More than 70% of patients report daily pain and stiffness.[67]

Fatigue is another common complaint, occurring in approximately 65% of AS patients. Most patients report their fatigue to be moderately severe. Increased levels of fatigue are associated with increased pain and stiffness and decreased functional capacity.[2, 3]

Fever and weight loss may occur during periods of active disease.

Inflammatory back pain

Inflammatory back pain is the most common symptom and the first manifestation in approximately 75% of patients.[68] The pain is typically dull and poorly localized to the gluteal and sacroiliac (SI) areas.

Symptoms associated with inflammatory back pain include insidious onset occurring over months or years, generally with at least 3 months of symptoms before presentation. Most patients have mild chronic disease or intermittent flares with periods of remission. The spinal disease is rarely persistently active.

The pain often begins unilaterally and intermittently, and generally begins in the lumbosacral region (SI joints). However, as the disease progresses, it becomes more persistent and bilateral and progresses more proximally,[3] with ossification of the annulus fibrosus that results in fusion of the spine (bamboo spine).

Patients commonly experience morning stiffness lasting at least 30 minutes, improvement of symptoms with moderate physical activity, and diffuse nonspecific radiation of pain into both buttocks. Patients often experience stiffness and pain that awakens them in the early morning, a distinctive symptom not generally found in patients with mechanical back pain.

New criteria to define inflammatory back pain have been proposed; when two of the four criteria are present, they yield a sensitivity of 70.3% and a specificity of 81.2%.[69] These criteria include the following:

  • Morning stiffness that lasts more than 30 minutes
  • Improvement of back pain with exercise but not rest
  • Nocturnal back pain during the second half of the night only
  • Alternating buttock pain

Acute onset of pain, exacerbation of symptoms with activity, and radicular radiation of pain suggest a mechanical or degenerative process such as disc disease.

Peripheral enthesitis and arthritis

Peripheral musculoskeletal involvement occurs in 30-50% of all patients. Peripheral enthesitis is the basic pathologic process, involving inflammation at the site of insertion of ligaments and tendons on to bone. This often progresses from erosion and osteitis to ossification, resulting in telltale radiological signs of periosteal new bone formation.

The following sites are commonly involved:

  • Achilles tendon insertion
  • Insertion of the plantar fascia on the calcaneus or the metatarsal heads
  • Base of the fifth metatarsal head
  • Tibial tuberosity
  • Superior and inferior poles of the patella
  • Iliac crest

Other sites of involvement include the following:

  • Greater trochanter
  • Ischial tuberosity
  • Costochondral junctions
  • Distal scapula
  • Lateral epicondyle
  • Distal ulna

Enthesopathic lesions tend to be quite painful (eg, the plantar fascia when getting out of bed), especially in the morning. Some of the peripheral arthritis occurs at sites in which the major component is local enthesitis, as suggested by magnetic resonance imaging (MRI).

Joint involvement tends to occur most commonly in the hips, shoulders, and joints of the chest wall, including the acromioclavicular and sternoclavicular joints, and often occurs in the first 10 years of disease. Involvement of the hips and shoulders may result in joint damage with radiographic changes. Involvement of the hips and shoulder joints is more common in persons with juvenile-onset AS than in adult patients with AS.

Other peripheral joints are involved less frequently and to a milder degree, usually as an asymmetric oligoarthritis predominantly involving the lower extremities. Involvement of the temporomandibular joint occurs in approximately 10% of patients. Patients may complain of decreased range of motion (ROM) or jaw pain. Involvement of the costovertebral and costotransverse joints can lead to decreased ROM and restriction in respiration. Patients may complain of difficulty breathing or chest tightness.

Next

Physical Examination

Chronic involvement of the spine eventually can lead to decreases in ROM and fusion of the vertebral bodies. Involvement of the cervical and upper thoracic spine can lead to fusion of the neck in a stooped forward-flexed position (see the images below). This position can significantly limit the patient’s ability to ambulate and look straight ahead.

Patient with ankylosing spondylitis affecting cerv Patient with ankylosing spondylitis affecting cervical and upper thoracic spine. Patient's spine has been fused in flexed position.
Posterior view of patient with ankylosing spondyli Posterior view of patient with ankylosing spondylitis affecting cervical and upper thoracic spine. Patient's spine has been fused in flexed position.

Articular manifestations

Focus the physical examination on active and passive ROM of the axial and peripheral joints. Tenderness in the SI joints is common. Peripheral enthesitis is often identified by tenderness and swelling of tendons and ligamentous insertions.[4]

Spine

Stiffness of the spine and kyphosis resulting in a stooped posture are characteristic of advanced-stage AS. Earlier in the course of the disease, indirect evidence of sacroiliitis and spondylitis may be observed, including tenderness of the SI (elicited by either direct pressure or indirect compression) or a limited spinal ROM. Some patients may have a deformity of the spine, most commonly with a loss of lumbar lordosis and accentuated thoracic kyphosis.

The ROM of the lumbar spine can be assessed using various methods, of which the Schober test is the most popular. (This test is not specific for AS.)

Perform the Schober test by marking a 10-cm length of the lumbar spine (with the patient in the erect position), starting at the fifth lumbar spinous process. Instruct the patient to flex his or her spine maximally. Remeasure the distance between the marks. Normal flexion increases the distance by at least 5 cm. Loss of chest expansion (< 3-cm difference between minimum and maximum chest diameter) is usually found only in patients with late-stage disease and is generally not helpful in diagnosis.

Peripheral entheses and joints

Peripheral enthesitis occurs in approximately 33% of patients. These lesions are painful and tender upon examination and may be associated with swelling of the tendon or ligament insertion.

The most common and characteristic peripheral sites of enthesitis are the insertion of the Achilles tendon on the calcaneus and the insertion of the plantar fascia on the calcaneus. Certain anatomic areas may be more prone to enthesitis because of biomechanical stress. Carefully examine patients for tenderness upon palpation.

Enthesitis and synovitis account for some of the peripheral joint involvement. Peripheral joint disease occurs in 33% of patients, most commonly in the hips. Hip involvement usually occurs in the first 10 years of the disease course and is typically bilateral.

Other joints may be involved, including the shoulder girdle (glenohumeral, acromioclavicular, and sternoclavicular joints), costovertebral joints, costosternal junctions, manubriosternal joints, symphysis pubis, and temporal mandibular joints. Additionally peripheral joints are uncommonly involved; when they are involved it is in an asymmetric oligoarticular pattern.

Dactylitis (sausage digit) is very uncommon in patients with AS. Isolated small-joint involvement of the hands, feet, or dactylitis strongly suggests reactive arthritis (ReA), psoriatic arthritis (PsA), or undifferentiated spondyloarthropathy (USpA).

Destructive arthritis may affect the hips or shoulder girdle, which may result in limited range of motion and flexion deformities.

Extra-articular manifestations

Screen for extra-articular manifestations of AS by performing specific examinations (eg, ophthalmologic, cardiac, and gastrointestinal(GI) examinations). Such manifestations may include the following:

  • Uveitis
  • Cardiovascular disease
  • Pulmonary disease
  • Renal disease
  • Neurologic disease
  • GI disease

Uveitis

Uveitis (also called iritis or iridocyclitis) is the most common extra-articular manifestation of AS, occurring in 20-30% of patients.[70, 71] Of all patients with acute anterior uveitis, 30-50% have or will develop AS. The incidence is much higher in individuals who are HLA-B27 positive (84-90%). Patients with uveitis may also have or may develop other spondyloarthropathies, including ReA (5-10%), USpA (2-5%), and PsA (< 1%), although this is less common. Isolated inflammatory bowel disease (IBD) is also associated with uveitis.

The uveitis associated with AS is usually acute in presentation and unilateral, and symptoms include a painful red eye with photophobia, increased lacrimation, and blurred vision. The involvement is usually anterior, rarely including posterior elements. Attacks usually resolve over 2-3 months with treatment, and residual visual impairment is unlikely unless treatment is inadequate or delayed. Recurrences are common.

The uveitis that develops in ReA is similar to the uveitis that develops in AS, whereas the uveitis that develops in PsA and in spondyloarthropathy associated with IBD tends to be more chronic and bilateral and often involves posterior elements.

Cardiovascular involvement

Clinically significant cardiovascular involvement occurs in fewer than 10% of AS patients, typically those with severe long-standing disease. However, subclinical disease can be detected in many patients and may occur as an isolated clinical entity in association with HLA-B27.

Aortitis of the ascending aorta may lead to distortion of the aortic ring, resulting in aortic valve insufficiency. Mitral valve insufficiency rarely occurs. Fibrosis of the conduction system may result in various degrees of atrioventricular block, including complete heart block.

Pulmonary involvement

Restrictive lung disease may occur in patients with late-stage AS, with costovertebral and costosternal involvement causing limited chest expansion. Bilateral apical pulmonary fibrosis rarely occurs in the setting of severe disease. These lesions may cavitate and become colonized by bacteria or fungi (eg, Aspergillus), resulting in cough, dyspnea, and hemoptysis.

Renal involvement

Amyloidosis is a very rare complication of AS in patients with severe, active, and long-standing disease. These patients generally have active spondylitis, active peripheral joint involvement, a higher erythrocyte sedimentation rate (ESR), and an increased C-reactive protein (CRP) level. This may result in renal dysfunction with proteinuria and renal insufficiency or failure. Immunoglobulin A (IgA) nephropathy has been reported in association with AS.

Neurologic involvement

Neurologic complications may occur secondary to fractures of a fused spine, which may be very difficult to detect with standard radiography. Patients are also prone to atlantoaxial subluxation, which may result in cervical myelopathy. Cauda equina syndrome may also occur in patients with severe long-standing AS.

Gastrointestinal involvement

Asymptomatic inflammation of the proximal colon and terminal ileum has been observed in as many as 60% of patients with AS and USpA. Patients with established AS only rarely develop Crohn disease or ulcerative colitis.

Metabolic bone disease

Although AS is associated with new bone formation at sites of spinal and peripheral enthesitis, osteopenia and osteoporosis have been documented in patients with long-standing spondylitis, resulting in an increased risk of fracture. Reevaluate patients with AS who have severe spondylitis and who present with acute exacerbations of back or neck pain for possible fracture, especially in the setting of trauma. Standard radiography may not be revealing; computed tomography (CT) or MRI may be required to aid in diagnosis.

Heterotopic bone formation may occur after total hip replacement.

Ankylosing spondylitis in women

According to radiographic survey studies, prevalence rates of AS are approximately equal in men and women. Clinical AS is more common in men than in women, with a male-to-female ratio of approximately 3:1. Studies indicate that male and female AS patients show similar clinical manifestations, although men have more severe radiographic changes in the spine and hips than women.[72]

Juvenile ankylosing spondylitis

Juvenile AS is clinically similar to adult AS.[73, 74] In approximately 10-20% of all cases, symptom onset occurs before age 16 years. The male-to-female ratio of 3:1 is similar to that of adults.

Enthesitis is prominent early in the course of the disease, while spinal symptoms and limitation of motion may not be present until several years later. Peripheral arthritis, especially in the lower extremities, and dactylitis are more common in children than in adults. Systemic manifestations (eg, fever, weight loss, anemia, leukocytosis) occur at disease onset in children more frequently than in adults.

Initial radiography findings of the sacroiliac regions and spine are often normal or difficult to interpret in children. These factors make a definitive diagnosis of AS difficult in children. In such cases, the presence of HLA-B27 would be supportive of the diagnosis of a spondyloarthropathy.

Some children exhibit a syndrome of seronegativity, enthesopathy, and arthropathy (SEA) that is clinically similar to USpA. These children often develop AS over time, with typical radiographic changes, usually by early adulthood. A variant, ankylosing tarsitis, is described in children who present with enthesitis in the tarsal region. This can lead to ossification, which results in a characteristic radiographic appearance. When tarsal inflammation is part of the clinical picture in a child or adult, strongly consider one of the spondyloarthropathies.

Undifferentiated spondyloarthropathy

USpA has features consistent with the spondyloarthropathies, but affected patients do not fulfill criteria for any specific spondyloarthropathy.[65, 75]

USpA may represent an early phase or incomplete form of AS or another spondyloarthropathy. In fact, several studies of USpA included many patients who probably should have been diagnosed with AS, ReA, or IBD-associated spondyloarthropathy, which made the clinical description very ambiguous. However, subsequent data suggest that these patients may represent a distinct disease entity on the basis of demographic and clinical criteria.

Although no specific criteria are identified, using modified Amor criteria can be helpful in confirming a clinical diagnosis of USpA (see Table 3 below).[54, 76, 5]

Table 3. Diagnostic Criteria for Undifferentiated Spondyloarthropathy Using Modified Amor Criteria (Open Table in a new window)

Inclusion Criteria Exclusion Criteria
Inflammatory back pain 1 point Diagnosis of specific spondyloarthropathy
Unilateral buttock pain 1 point Sacroiliitis on radiograph = grade 2
Alternating buttock pain 2 points Precipitating genitourinary/gastrointestinal infection
Enthesitis 2 points Psoriasis
Peripheral arthritis 2 points Keratoderma blennorrhagicum
Dactylitis (sausage digit) 2 points Inflammatory bowel disease (Crohn disease or ulcerative colitis)
Acute anterior uveitis 2 points Positive rheumatoid factor
HLA-B27 –positive or family history of spondyloarthropathy 2 points Positive antinuclear antibody, titer > 1:80
Good response to nonsteroidal anti-inflammatory drugs 2 points  
Diagnosis of spondyloarthropathy with 6 or more points

The age of onset for USpA extends over a very wide range, with the peak onset at approximately age 50 years. The male-to-female ratio is 1:3. The onset is usually insidious, and, even after years of active disease, sacroiliitis and spondylitis are either absent or appear very mild on routine radiography.

Clinical manifestations of undifferentiated spondyloarthropathy include inflammatory back pain (90%), buttock pain (80%), enthesitis (85%), peripheral arthritis (35%), dactylitis (17%), and fatigue (55%) (see Table 4 below). Extra-articular manifestations are uncommon, occurring in fewer than 10% of patients, and include acute anterior uveitis (1-2%), oral ulcers, rash, nonspecific IBD, pleuritis, and pericarditis.

Table 4. Clinical and Laboratory Features of Undifferentiated Spondyloarthropathy (Open Table in a new window)

Clinical or Laboratory Feature Frequency
Inflammatory back pain 90%
Buttock pain 80%
Enthesitis 75%
Peripheral arthritis 40%
Dactylitis (sausage digits) 20%
Acute anterior uveitis 1-2%
Fatigue 55%
Elevated ESR 32%
HLA-B27 –positive 25%
ESR = erythrocyte sedimentation rate.

Findings of laboratory studies are generally unremarkable except for the presence of an elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level. HLA-B27 antigen is positive only in approximately 20-25% of patients.

These factors, especially the late age of onset, female predominance, and low HLA-B27 positivity, suggest that USpA is distinct from AS and the other classic spondyloarthropathies.

In addition, when these patients are observed over long periods, they rarely develop clinical manifestations or radiographic changes that result in a change of diagnosis. Occasionally, radiographs show evidence of periosteal new bone formation at sites of enthesitis, especially at the insertion of the Achilles tendon or plantar fascia on the calcaneus, or early syndesmophytes on the lumbar spine without bridging.

Although most patients with USpA (>75%) have chronic, active disease and require long-term therapy for ongoing symptoms, some patients have mild and intermittent symptoms that require intermittent symptomatic therapy. These episodes may last from 1-2 weeks to several months, with long asymptomatic periods that do not require therapy.

Most patients respond well to nonsteroidal anti-inflammatory drugs (NSAIDs). The majority maintain good function without progressive disease or clinically significant radiographic changes. A small minority of patients do not respond well to or tolerate NSAIDs. In these patients, treatment progression is similar to that in AS patients, including the use of sulfasalazine, methotrexate, and tumor necrosis factor alpha (TNF-α) antagonists, although no well-designed clinical trials have been conducted on the treatment of USpA.

Complications

Complications may occur from spinal and articular disease or extra-articular manifestations. The most common complications of AS include pain, stiffness, and limited functional disability. All of these complications can be reduced through a proper treatment plan consisting of medications, exercise, and education. Patients with AS often have additional coexisting diseases, including other spondyloarthropathies. IBD is also more common in these individuals.

A small minority of patients develop spinal fusion, which may result in severe kyphosis and limited motion of the spine, including the cervical region. The fused spine is more susceptible to fracture, even with relatively minor trauma. Occasionally, the hip and shoulder joints develop severe arthritis, requiring total joint replacement.

Extra-articular manifestations (eg, recurrent uveitis, cardiovascular involvement, pulmonary involvement, amyloidosis) rarely result in significant morbidity or mortality.

Fracture

The most serious complication related to AS is a vertebral fracture. Vertebral fractures associated with AS are most common in the cervical spine and are usually the result of a minor fall. For a patient with advanced AS, minor trauma is capable of producing an unstable spinal injury with the risk of neurologic injury or death.

Vertebral fractures are more likely to produce spinal instability in an individual with AS than in an individual without AS, because in advanced AS, the fracture occurs as in a long-bone fracture. The fracture disrupts not only the bony elements but also the ligamentous supports that have become ossified. Without the ligamentous support, the spine becomes grossly unstable, and this instability can lead to severe neurologic injury, including paralysis and death.

Proper diagnosis of a vertebral fracture is often delayed because the patient does not realize the need to seek medical help, because the physician fails to consider the possibility of a vertebral fracture after minor trauma, or because the fracture is difficult to visualize on radiography.

In some case, radiographic diagnosis is made difficult by the presence of osteopenia and spinal deformity. Additionally, immobility of the glenohumeral joint can interfere with the ability to obtain an adequate “swimmer’s view” to visualize the lower cervical spine. In many cases, CT scans are required for assessment of the spine. The possibility of fractures in the transverse plane suggests the need for sagittal reformatting of the images. If visualization is still inadequate, MRI and bone scans may be helpful.

Spondylodiscitis

Spondylodiscitis (also referred to as Andersson lesion) is a destructive diskovertebral lesion with an estimated symptomatic prevalence of 1-10% in patients with AS.[77, 78] The prevalence in asymptomatic patients is unknown.

The etiology of spondylodiscitis is debatable. Some authors argue that these lesions are the result of mechanical factors, whereas others believe that the inflammation caused by AS is the source. Each of these possible etiologies is likely capable of producing similar lesions.

Spondylodiscitis can occur at any time, regardless of the severity of AS. Patients generally present with acute-onset localized pain. Pain is exacerbated with movement and is alleviated with rest. These symptoms can be easily differentiated from the normal pain pattern of AS, which is insidious in onset and relieved with motion.

Radiologic evidence of spondylodiscitis varies with the disease progression but can include destructive foci throughout the diskovertebral junction, bony sclerosis on both sides of the affected disc level, widening or narrowing of the disc space, and osteolysis of the vertebral bodies.[77, 79] Plain radiographs are not always sufficient to identify spondylodiscitis. CT scans, MRI, and bone scans are often helpful in confirming the diagnosis.

The prognosis is generally good with conservative therapy, including rest, administration of NSAIDs, and physical therapy. Surgical treatment is indicated only in cases where there is evidence of spinal instability or neurologic injury.

Previous
 
 
Contributor Information and Disclosures
Author

Lawrence H Brent, MD Associate Professor of Medicine, Jefferson Medical College of Thomas Jefferson University; Chair, Program Director, Department of Medicine, Division of Rheumatology, Albert Einstein Medical Center

Lawrence H Brent, MD is a member of the following medical societies: American Association for the Advancement of Science, American Association of Immunologists, American College of Physicians, American College of Rheumatology

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Janssen<br/>Serve(d) as a speaker or a member of a speakers bureau for: Abbvie; Genentech; Pfizer; Questcor.

Coauthor(s)

Rajni Kalagate, MD Resident Physician, Department of Internal Medicine, Albert Einstein Medical Center

Rajni Kalagate, MD is a member of the following medical societies: American Academy of Pediatrics, Indian Medical Association

Disclosure: Nothing to disclose.

Ruchika Patel, MD Attending Physician, Division of Rheumatology, Einstein Medical Center

Ruchika Patel, MD is a member of the following medical societies: American College of Physicians, American College of Rheumatology, Philadelphia Rheumatism Society

Disclosure: Nothing to disclose.

Chief Editor

Herbert S Diamond, MD Visiting Professor of Medicine, Division of Rheumatology, State University of New York Downstate Medical Center; Chairman Emeritus, Department of Internal Medicine, Western Pennsylvania Hospital

Herbert S Diamond, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American College of Rheumatology, American Medical Association, Phi Beta Kappa

Disclosure: Nothing to disclose.

Acknowledgements

Jason C Eck, DO, MS Assistant Professor, Department of Orthopedics and Physical Rehabilitation, UMass Memorial Medical Center

Jason C Eck, DO, MS is a member of the following medical societies: American Osteopathic Academy of Orthopedics, American Osteopathic Association, International Society for the Study of the Lumbar Spine, and North American Spine Society

Disclosure: Medtronic Honoraria Speaking and teaching

Elliot Goldberg, MD Dean of the Western Pennsylvania Clinical Campus, Professor, Department of Medicine, Temple University School of Medicine

Elliot Goldberg, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, and American College of Rheumatology

Disclosure: Nothing to disclose.

Scott D Hodges, DO Consulting Surgeon, Department of Orthopedic Surgery, Center for Sports Medicine and Orthopedics

Scott D Hodges, DO is a member of the following medical societies: American Academy of Disability Evaluating Physicians, American Medical Association, American Osteopathic Association, American Spinal Injury Association, North American Spine Society, Southern Medical Association, Southern Orthopaedic Association, and Tennessee Medical Association

Disclosure: Medtronic Royalty Consulting; Biomet Spine Royalty Consulting

S Craig Humphreys, MD Orthopedic Spine Surgeon, Department of Orthopedic Surgery, Center for Sports Medicine and Orthopedics

S Craig Humphreys, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Orthopaedic Surgeons, American Medical Association, American Spinal Injury Association, North American Spine Society, Southern Medical Association, Southern Orthopaedic Association, and Tennessee Medical Association

Disclosure: Nothing to disclose.

James F Kellam, MD Vice-Chair, Department of Orthopedic Surgery, Director of Orthopedic Trauma and Education, Carolinas Medical Center

James F Kellam, MD is a member of the following medical societies: American Academy of Orthopaedic Surgeons, Orthopaedic Trauma Association, and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Kristine M Lohr, MD, MS Professor, Department of Internal Medicine, Center for the Advancement of Women's Health and Division of Rheumatology, Director, Rheumatology Training Program, University of Kentucky College of Medicine

Kristine M Lohr, MD, MS is a member of the following medical societies: American College of Physicians and American College of Rheumatology

Disclosure: Nothing to disclose.

William O Shaffer, MD Professor, Vice-Chairman and Residency Program Director, Department of Orthopedic Surgery, University of Kentucky at Lexington

William O Shaffer, MD is a member of the following medical societies: American Academy of Orthopaedic Surgeons, American Orthopaedic Association, International Society for the Study of the Lumbar Spine, Kentucky Medical Association, Kentucky Orthopaedic Society, North American Spine Society, Southern Medical Association, and Southern Orthopaedic Association

Disclosure: DePuySpine 1997-2007 (not presently) Royalty Consulting; DePuySpine 2002-2007 (closed) Grant/research funds SacroPelvic Instrumentation Biomechanical Study; DePuyBiologics 2005-2008 (closed) Grant/research funds Healos study just closed; DePuySpine 2009 Consulting fee Design of Offset Modification of Expedium

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References
  1. Passalent LA, Soever LJ, O'Shea FD, Inman RD. Exercise in ankylosing spondylitis: discrepancies between recommendations and reality. J Rheumatol. 2010 Apr. 37(4):835-41. [Medline].

  2. Jones SD, Koh WH, Steiner A, Garrett SL, Calin A. Fatigue in ankylosing spondylitis: its prevalence and relationship to disease activity, sleep, and other factors. J Rheumatol. 1996 Mar. 23(3):487-90. [Medline].

  3. Mengshoel AM, Førre O. Pain and fatigue in patients with rheumatic disorders. Clin Rheumatol. 1993 Dec. 12(4):515-21. [Medline].

  4. van der Linden S, van der Heijde D. Ankylosing spondylitis. Clinical features. Rheum Dis Clin North Am. 1998 Nov. 24(4):663-76, vii. [Medline].

  5. Collantes-Estevez E, Cisnal del Mazo A, Munoz-Gomariz E. Assessment of 2 systems of spondyloarthropathy diagnostic and classification criteria (Amor and ESSG) by a Spanish multicenter study. European Spondyloarthropathy Study Group. J Rheumatol. 1995 Feb. 22(2):246-51. [Medline].

  6. Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991 Oct. 34(10):1218-27. [Medline].

  7. van der Heijde D, Spoorenberg A. Plain radiographs as an outcome measure in ankylosing spondylitis. J Rheumatol. 1999 Apr. 26(4):985-7. [Medline].

  8. Naredo E, Batlle-Gualda E, García-Vivar ML, García-Aparicio AM, Fernández-Sueiro JL, Fernández-Prada M, et al. Power Doppler ultrasonography assessment of entheses in spondyloarthropathies: response to therapy of entheseal abnormalities. J Rheumatol. 2010 Oct. 37(10):2110-7. [Medline].

  9. Vinson EN, Major NM. MR imaging of ankylosing spondylitis. Semin Musculoskelet Radiol. 2003 Jun. 7(2):103-13. [Medline].

  10. Geijer M, Gothlin GG, Gothlin JH. The clinical utility of computed tomography compared to conventional radiography in diagnosing sacroiliitis. A retrospective study on 910 patients and literature review. J Rheumatol. 2007 Jul. 34(7):1561-5. [Medline].

  11. Van Royen BJ, De Gast A. Lumbar osteotomy for correction of thoracolumbar kyphotic deformity in ankylosing spondylitis. A structured review of three methods of treatment. Ann Rheum Dis. 1999 Jul. 58(7):399-406. [Medline]. [Full Text].

  12. Shih LY, Chen TH, Lo WH, Yang DJ. Total hip arthroplasty in patients with ankylosing spondylitis: longterm followup. J Rheumatol. 1995 Sep. 22(9):1704-9. [Medline].

  13. Cawley MI, Chalmers TM, Ball J. Destructive lesions of vertebral bodies in ankylosing spondylitis. Ann Rheum Dis. 1971 Sep. 30(5):539-40. [Medline]. [Full Text].

  14. Hanson JA, Mirza S. Predisposition for spinal fracture in ankylosing spondylitis. AJR Am J Roentgenol. 2000 Jan. 174(1):150. [Medline].

  15. Hunter T. The spinal complications of ankylosing spondylitis. Semin Arthritis Rheum. 1989 Dec. 19(3):172-82. [Medline].

  16. Sutherland RI, Matheson D. Inflammatory involvement of vertebrae in ankylosing spondylitis. J Rheumatol. 1975 Sep. 2(3):296-302. [Medline].

  17. van der Linden S, van der Heijde D. Clinical aspects, outcome assessment, and management of ankylosing spondylitis and postenteric reactive arthritis. Curr Opin Rheumatol. 2000 Jul. 12(4):263-8. [Medline].

  18. Schlosstein L, Terasaki PI, Bluestone R, et al. High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med. 1973 Apr 5. 288(14):704-6. [Medline].

  19. Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD. Ankylosing spondylitis and HL-A 27. Lancet. 1973 Apr 28. 1(7809):904-7. [Medline].

  20. Caffrey MF, James DC. Human lymphocyte antigen association in ankylosing spondylitis. Nature. 1973 Mar 9. 242(5393):121. [Medline].

  21. Alvarez I, López de Castro JA. HLA-B27 and immunogenetics of spondyloarthropathies. Curr Opin Rheumatol. 2000 Jul. 12(4):248-53. [Medline].

  22. McGonagle D, Gibbon W, Emery P. Classification of inflammatory arthritis by enthesitis. Lancet. 1998 Oct 3. 352(9134):1137-40. [Medline].

  23. Muñoz-Villanueva MC, Muñoz-Gomariz E, Escudero-Contreras A, et al. Biological and clinical markers of disease activity in ankylosing spondylitis. J Rheumatol. 2003 Dec. 30(12):2729-32. [Medline]. [Full Text].

  24. Palazzi C, Olivieri I, D'Amico E, Pennese E, Petricca A. Management of reactive arthritis. Expert Opin Pharmacother. 2004 Jan. 5(1):61-70. [Medline].

  25. McGonagle D, Emery P. Enthesitis, osteitis, microbes, biomechanics, and immune reactivity in ankylosing spondylitis. J Rheumatol. 2000 Oct. 27(10):2302-4. [Medline].

  26. O'Neill TW, Bresnihan B. The heart in ankylosing spondylitis. Ann Rheum Dis. 1992 Jun. 51(6):705-6. [Medline]. [Full Text].

  27. Khan MA. Update on spondyloarthropathies. Ann Intern Med. 2002 Jun 18. 136(12):896-907. [Medline].

  28. Wordsworth P. Genes in the spondyloarthropathies. Rheum Dis Clin North Am. 1998 Nov. 24(4):845-63. [Medline].

  29. Reveille JD. The genetic basis of ankylosing spondylitis. Curr Opin Rheumatol. 2006 Jul. 18(4):332-41. [Medline].

  30. Brionez TF, Reveille JD. The contribution of genes outside the major histocompatibility complex to susceptibility to ankylosing spondylitis. Curr Opin Rheumatol. 2008 Jul. 20(4):384-91. [Medline].

  31. Brown MA. Breakthroughs in genetic studies of ankylosing spondylitis. Rheumatology (Oxford). 2008 Feb. 47(2):132-7. [Medline].

  32. Reveille JD, Ball EJ, Khan MA. HLA-B27 and genetic predisposing factors in spondyloarthropathies. Curr Opin Rheumatol. 2001 Jul. 13(4):265-72. [Medline].

  33. Jaakkola E, Herzberg I, Laiho K, Barnardo MC, Pointon JJ, Kauppi M, et al. Finnish HLA studies confirm the increased risk conferred by HLA-B27 homozygosity in ankylosing spondylitis. Ann Rheum Dis. 2006 Jun. 65(6):775-80. [Medline].

  34. Reveille JD, Arnett FC. Spondyloarthritis: update on pathogenesis and management. Am J Med. 2005 Jun. 118(6):592-603. [Medline].

  35. van Gaalen FA, Verduijn W, Roelen DL, Böhringer S, Huizinga TW, van der Heijde DM, et al. Epistasis between two HLA antigens defines a subset of individuals at a very high risk for ankylosing spondylitis. Ann Rheum Dis. 2012 Aug 21. [Medline].

  36. Ebringer A. The relationship between Klebsiella infection and ankylosing spondylitis. Baillieres Clin Rheumatol. 1989 Aug. 3(2):321-38. [Medline].

  37. Timms AE, Crane AM, Sims AM, Cordell HJ, Bradbury LA, Abbott A, et al. The interleukin 1 gene cluster contains a major susceptibility locus for ankylosing spondylitis. Am J Hum Genet. 2004 Oct. 75(4):587-95. [Medline].

  38. Maksymowych WP, Rahman P, Reeve JP, Gladman DD, Peddle L, Inman RD. Association of the IL1 gene cluster with susceptibility to ankylosing spondylitis: an analysis of three Canadian populations. Arthritis Rheum. 2006 Mar. 54(3):974-85. [Medline].

  39. Burton PR, Clayton DG, Cardon LR, Craddock N, Deloukas P, Duncanson A, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet. 2007 Nov. 39(11):1329-37. [Medline].

  40. Rahman P, Inman RD, Gladman DD, Reeve JP, Peddle L, Maksymowych WP. Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum. 2008 Apr. 58(4):1020-5. [Medline].

  41. Rueda B, Orozco G, Raya E, Fernandez-Sueiro JL, Mulero J, Blanco FJ, et al. The IL23R Arg381Gln non-synonymous polymorphism confers susceptibility to ankylosing spondylitis. Ann Rheum Dis. 2008 Oct. 67(10):1451-4. [Medline].

  42. Karaderi T, Harvey D, Farrar C, Appleton LH, Stone MA, Sturrock RD, et al. Association between the interleukin 23 receptor and ankylosing spondylitis is confirmed by a new UK case-control study and meta-analysis of published series. Rheumatology (Oxford). 2009 Apr. 48(4):386-9. [Medline].

  43. Layh-Schmitt G, Colbert RA. The interleukin-23/interleukin-17 axis in spondyloarthritis. Curr Opin Rheumatol. 2008 Jul. 20(4):392-7. [Medline].

  44. Hammer RE, Maika SD, Richardson JA, et al. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell. 1990 Nov 30. 63(5):1099-112. [Medline].

  45. Khare SD, Luthra HS, David CS. Animal models of human leukocyte antigen B27-linked arthritides. Rheum Dis Clin North Am. 1998 Nov. 24(4):883-94, xi-xii. [Medline].

  46. Lories RJ. Animal models of spondyloarthritis. Curr Opin Rheumatol. 2006 Jul. 18(4):342-6. [Medline].

  47. Braun J, Bollow M, Remlinger G, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. 1998 Jan. 41(1):58-67. [Medline].

  48. Trontzas P, Andrianakos A, Miyakis S, et al. Seronegative spondyloarthropathies in Greece: a population-based study of prevalence, clinical pattern, and management. The ESORDIG study. Clin Rheumatol. 2005 Nov. 24(6):583-9. [Medline].

  49. De Angelis R, Salaffi F, Grassi W. Prevalence of spondyloarthropathies in an Italian population sample: a regional community-based study. Scand J Rheumatol. 2007 Jan-Feb. 36(1):14-21. [Medline].

  50. Taurog JD. The mystery of HLA-B27: if it isn't one thing, it's another. Arthritis Rheum. 2007 Aug. 56(8):2478-81. [Medline].

  51. Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007 Apr 21. 369(9570):1379-90. [Medline].

  52. Feldtkeller E, Khan MA, van der Heijde D, et al. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int. 2003 Mar. 23(2):61-6. [Medline].

  53. Dincer U, Cakar E, Kiralp MZ, Dursun H. Diagnosis delay in patients with ankylosing spondylitis: possible reasons and proposals for new diagnostic criteria. Clin Rheumatol. 2008 Apr. 27(4):457-62. [Medline].

  54. Rezaian MM, Brent LH. Undifferentiated spondyloarthropathy: Seven-year follow-up study of 357 patients. Arthritis Rheum. 2001. 44:S93.

  55. Braun J, Pincus T. Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol. 2002 Nov-Dec. 20(6 Suppl 28):S16-22. [Medline].

  56. Ringsdal VS, Helin P. Ankylosing spondylitis--education, employment and invalidity. Dan Med Bull. 1991 Jun. 38(3):282-4. [Medline].

  57. Wordsworth BP, Mowat AG. A review of 100 patients with ankylosing spondylitis with particular reference to socio-economic effects. Br J Rheumatol. 1986 May. 25(2):175-80. [Medline].

  58. McGuigan LE, Hart HH, Gow PJ, Kidd BL, Grigor RR, Moore TE. Employment in ankylosing spondylitis. Ann Rheum Dis. 1984 Aug. 43(4):604-6. [Medline]. [Full Text].

  59. Lehtinen K. Working ability of 76 patients with ankylosing spondylitis. Scand J Rheumatol. 1981. 10(4):263-5. [Medline].

  60. Verstappen SM, Watson KD, Lunt M, McGrother K, Symmons DP, Hyrich KL. Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2010 Aug. 49(8):1570-7. [Medline]. [Full Text].

  61. Gran JT, Skomsvoll JF. The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol. 1997 Jul. 36(7):766-71. [Medline].

  62. Guillemin F, Briançon S, Pourel J, Gaucher A. Long-term disability and prolonged sick leaves as outcome measurements in ankylosing spondylitis. Possible predictive factors. Arthritis Rheum. 1990 Jul. 33(7):1001-6. [Medline].

  63. Leirisalo-Repo M. Prognosis, course of disease, and treatment of the spondyloarthropathies. Rheum Dis Clin North Am. 1998 Nov. 24(4):737-51, viii. [Medline].

  64. Carette S, Graham D, Little H, Rubenstein J, Rosen P. The natural disease course of ankylosing spondylitis. Arthritis Rheum. 1983 Feb. 26(2):186-90. [Medline].

  65. Sampaio-Barros PD, Bertolo MB, Kraemer MH, et al. Undifferentiated spondyloarthropathies: a 2-year follow-up study. Clin Rheumatol. 2001. 20(3):201-6. [Medline].

  66. Mattey DL, Dawson SR, Healey EL, Packham JC. Relationship Between Smoking and Patient-reported Measures of Disease Outcome in Ankylosing Spondylitis. J Rheumatol. 2011 Dec. 38(12):2608-15. [Medline].

  67. O'Shea FD, Riarh R, Anton A, Inman RD. Assessing back pain: does the Oswestry Disability Questionnaire accurately measure function in ankylosing spondylitis?. J Rheumatol. 2010 Jun. 37(6):1211-3. [Medline].

  68. Calin A, Porta J, Fries JF, et al. Clinical history as a screening test for ankylosing spondylitis. JAMA. 1977 Jun 13. 237(24):2613-4. [Medline].

  69. Rudwaleit M, Metter A, Listing J, et al. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum. 2006 Feb. 54(2):569-78. [Medline].

  70. Martin TM, Smith JR, Rosenbaum JT. Anterior uveitis: current concepts of pathogenesis and interactions with the spondyloarthropathies. Curr Opin Rheumatol. 2002 Jul. 14(4):337-41. [Medline].

  71. Ali A, Samson CM. Seronegative spondyloarthropathies and the eye. Curr Opin Ophthalmol. 2007 Nov. 18(6):476-80. [Medline].

  72. Lee W, Reveille JD, Davis JC Jr, et al. Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort. Ann Rheum Dis. 2007 May. 66(5):633-8. [Medline].

  73. Burgos-Vargas R. The juvenile-onset spondyloarthritides. Rheum Dis Clin North Am. 2002 Aug. 28(3):531-60, vi. [Medline].

  74. Tse SM, Laxer RM. Juvenile spondyloarthropathy. Curr Opin Rheumatol. 2003 Jul. 15(4):374-9. [Medline].

  75. Zeidler H, Mau W, Khan MA. Undifferentiated spondyloarthropathies. Rheum Dis Clin North Am. 1992 Feb. 18(1):187-202. [Medline].

  76. Amor B, Dougados M, Mijiyawa M. [Criteria of the classification of spondylarthropathies]. Rev Rhum Mal Osteoartic. 1990 Feb. 57(2):85-9. [Medline].

  77. Rasker JJ, Prevo RL, Lanting PJ. Spondylodiscitis in ankylosing spondylitis, inflammation or trauma? A description of six cases. Scand J Rheumatol. 1996. 25(1):52-7. [Medline].

  78. Dihlmann W, Delling G. Discovertebral destructive lesions (so called Andersson lesions) associated with ankylosing spondylitis. Skel Radiol. 1978. 3:10-6.

  79. Agarwal AK, Reidbord HE, Kraus DR, Eisenbeis CH Jr. Variable histopathology of discovertebral lesion (spondylodiscitis) of ankylosing spondylitis. Clin Exp Rheumatol. 1990 Jan-Feb. 8(1):67-9. [Medline].

  80. Lipton S, Deodhar A. The New ASAS Classification Criteria for Axial and Peripheral Spondyloarthritis. Medscape Medical News. Available at http://www.medscape.com/viewarticle/776097_5. Accessed: November 4, 2014.

  81. Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011 Jan. 70(1):25-31. [Medline].

  82. van der Heijde D, Landewé R. Imaging in spondylitis. Curr Opin Rheumatol. 2005 Jul. 17(4):413-7. [Medline].

  83. [Guideline] Mandl P, Navarro-Compán V, Terslev L, et al. EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. Ann Rheum Dis. 2015 Apr 2. [Medline]. [Full Text].

  84. Ruof J, Stucki G. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol. 1999 Apr. 26(4):966-70. [Medline].

  85. Dougados M, Gueguen A, Nakache JP, et al. Clinical relevance of C-reactive protein in axial involvement of ankylosing spondylitis. J Rheumatol. 1999 Apr. 26(4):971-4. [Medline].

  86. Anwar F, Al-Khayer A, Joseph G, Fraser MH, Jigajinni MV, Allan DB. Delayed presentation and diagnosis of cervical spine injuries in long-standing ankylosing spondylitis. Eur Spine J. 2011 Mar. 20(3):403-7. [Medline]. [Full Text].

  87. Baraliakos X, Hermann KG, Landewé R, Listing J, Golder W, Brandt J, et al. Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences. Ann Rheum Dis. 2005 Aug. 64(8):1141-4. [Medline].

  88. Hermann KG, Landewé RB, Braun J, van der Heijde DM. Magnetic resonance imaging of inflammatory lesions in the spine in ankylosing spondylitis clinical trials: is paramagnetic contrast medium necessary?. J Rheumatol. 2005 Oct. 32(10):2056-60. [Medline].

  89. Kim NR, Choi JY, Hong SH, Jun WS, Lee JW, Choi JA, et al. "MR corner sign": value for predicting presence of ankylosing spondylitis. AJR Am J Roentgenol. 2008 Jul. 191(1):124-8. [Medline].

  90. Maksymowych WP, Chiowchanwisawakit P, Clare T, Pedersen SJ, Østergaard M, Lambert RG. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum. 2009 Jan. 60(1):93-102. [Medline].

  91. Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2006 Apr. 65(4):442-52. [Medline].

  92. Halm H, Metz-Stavenhagen P, Zielke K. Results of surgical correction of kyphotic deformities of the spine in ankylosing spondylitis on the basis of the modified arthritis impact measurement scales. Spine (Phila Pa 1976). 1995 Jul 15. 20(14):1612-9. [Medline].

  93. Hunter T, Dubo HI. Spinal fractures complicating ankylosing spondylitis. A long-term followup study. Arthritis Rheum. 1983 Jun. 26(6):751-9. [Medline].

  94. Escalas C, Trijau S, Dougados M. Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis. Rheumatology (Oxford). 2010 Jul. 49(7):1317-25. [Medline].

  95. Wanders A, Heijde D, Landewe R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005 Jun. 52(6):1756-65. [Medline].

  96. Sieper J, Klopsch T, Richter M, Kapelle A, Rudwaleit M, Schwank S, et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis. 2008 Mar. 67(3):323-9. [Medline]. [Full Text].

  97. Chen J, Liu C. Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheumatol. 2006 Apr. 33(4):722-31. [Medline].

  98. Clegg DO, Reda DJ, Weisman MH, Blackburn WD, Cush JJ, Cannon GW, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996 Dec. 39(12):2004-12. [Medline].

  99. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum. 1999 Nov. 42(11):2325-9. [Medline].

  100. Braun J, Pavelka K, Ramos-Remus C, Dimic A, Vlahos B, Freundlich B, et al. Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement. J Rheumatol. 2012 Apr. 39(4):836-40. [Medline].

  101. Inman RD, Maksymowych WP. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol. 2010 Jun. 37(6):1203-10. [Medline].

  102. Braun J, Davis J, Dougados M, et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2006 Mar. 65(3):316-20. [Medline].

  103. Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum. 2003 Apr. 48(4):1126-36. [Medline].

  104. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002 May 2. 346(18):1349-56. [Medline].

  105. Davis JC, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003 Nov. 48(11):3230-6. [Medline].

  106. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005 Feb. 52(2):582-91. [Medline].

  107. Braun J, Landewé R, Hermann KG, et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum. 2006 May. 54(5):1646-52. [Medline].

  108. Gengenbacher M, Sebald HJ, Villiger PM, Hofstetter W, Seitz M. Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis. 2008 May. 67(5):620-4. [Medline].

  109. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006 Jul. 54(7):2136-46. [Medline].

  110. Inman RD, Davis JC Jr, Heijde D, Diekman L, Sieper J, Kim SI, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008 Nov. 58(11):3402-12. [Medline].

  111. Medscape News. FDA clears certolizumab (Cimzia) for ankylosing spondylitis. Medscape. Available at http://www.medscape.com/viewarticle/812822. Accessed: October 18, 2013.

  112. Landewé R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis. 2013 Sep 6. [Medline]. [Full Text].

  113. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Emery P, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis. 2006 Nov. 65 Suppl 3:iii2-15. [Medline].

  114. Kelly JC. Ankylosing Spondylitis: Prolonged Anti-TNF Stops Damage. Medscape Medical News. Jun 22 2013. Available at http://www.medscape.com/viewarticle/808219. Accessed: July 30, 2013.

  115. Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, et al. The Impact of TNF-inhibitors on radiographic progression in Ankylosing Spondylitis. Arthritis Rheum. 2013 Jul 1. [Medline].

  116. Chen J, Liu C, Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev. 2006 Oct 18. CD004524. [Medline].

  117. van Denderen JC, van der Paardt M, Nurmohamed MT, de Ryck YM, Dijkmans BA, van der Horst-Bruinsma IE. Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann Rheum Dis. 2005 Dec. 64(12):1761-4. [Medline].

  118. van Denderen JC, Visman IM, Nurmohamed MT, Suttorp-Schulten MS, van der Horst-Bruinsma IE. Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis. J Rheumatol. 2014 Sep. 41(9):1843-8. [Medline].

  119. van der Heijde D, Dougados M, Davis J, Weisman MH, Maksymowych W, Braun J, et al. ASsessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis. Arthritis Rheum. 2005 Feb. 52(2):386-94. [Medline].

  120. Zochling J, Braun J. Assessments in ankylosing spondylitis. Best Pract Res Clin Rheumatol. 2007 Aug. 21(4):699-712. [Medline].

  121. Zochling J. Assessment and treatment of ankylosing spondylitis: current status and future directions. Curr Opin Rheumatol. 2008 Jul. 20(4):398-403. [Medline].

  122. Dagfinrud H, Kvien TK, Hagen KB. The Cochrane review of physiotherapy interventions for ankylosing spondylitis. J Rheumatol. 2005 Oct. 32(10):1899-906. [Medline].

  123. Dagfinrud H, Kvien TK, Hagen KB. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev. 2008 Jan 23. CD002822. [Medline].

  124. [Guideline] Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2015 Sep 24. [Medline]. [Full Text].

  125. Goodman SM, Zhu R, Figgie MP, Huang WT, Mandl LA. Short-term Total Hip Replacement Outcomes in Ankylosing Spondylitis. J Clin Rheumatol. 2014 Oct. 20(7):363-8. [Medline].

  126. Hidding A, van der Linden S, Gielen X, et al. Continuation of group physical therapy is necessary in ankylosing spondylitis: results of a randomized controlled trial. Arthritis Care Res. 1994 Jun. 7(2):90-6. [Medline].

  127. Kisacik B, Tufan A, Kalyoncu U, et al. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine. 2008 May. 75(3):291-4. [Medline].

  128. Kraag G, Stokes B, Groh J, Helewa A, Goldsmith C. The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis--a randomized controlled trial. J Rheumatol. 1990 Feb. 17(2):228-33. [Medline].

  129. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med. 2015 Dec 24. 373 (26):2534-48. [Medline].

 
Previous
Next
 
The family of spondyloarthropathies
This radiograph of the lumbar spine of a patient with end-stage ankylosing spondylitis shows bridging syndesmophytes, resulting in bamboo spine.
This radiograph of the cervical spine of a patient with ankylosing spondylitis shows fusion of vertebral bodies due to bridging syndesmophytes.
This 15-year-old female patient presented with recent onset of right-sided low back pain. Plain radiography findings were normal.
MRI of the same patient whose radiography findings were normal (previous image). She underwent further evaluation, including MRI. The MRI (short tau inversion recovery [STIR]) showed increased sinal intensity in the right sacroiliac joint, revealing sacroiliitis. Other laboratory study findings were essentially normal. The patient was started on indomethacin and rapidly improved.
Patient with ankylosing spondylitis affecting cervical and upper thoracic spine. Patient's spine has been fused in flexed position.
Posterior view of patient with ankylosing spondylitis affecting cervical and upper thoracic spine. Patient's spine has been fused in flexed position.
Anteroposterior radiograph of sacroiliac joint of patient with ankylosing spondylitis. Bilateral sacroiliitis with sclerosis can be observed.
Anteroposterior radiograph of spine of patient with ankylosing spondylitis. Ossification of anulus fibrosus can be observed at multiple levels, which has led to fusion of spine with abnormal curvature.
Anteroposterior radiograph of spine of patient with ankylosing spondylitis. Ossification of anulus fibrosus at multiple levels and squaring of vertebral bodies can be observed.
Anteroposterior radiograph of spine of patient with ankylosing spondylitis.
Anteroposterior (left) and lateral (right) radiographs of patient with ankylosing spondylitis.
Radiographs of hand (top) and arm (bottom) of patient with peripheral involvement of ankylosing spondylitis. Fusion of joint spaces and deformity can be observed.
Sagittal MRI of thoracolumbar spine of a patient with ankylosing spondylitis. Degenerative disc disease and bridging osteophytes can be observed at multiple levels.
Radiograph shows vertebral fracture in patient with ankylosing spondylitis.
Table 1. Association of Spondyloarthropathies With HLA-B27
Population or Disease Entity HLA-B27 –Positive
Healthy whites 8%
Healthy African Americans 4%
Ankylosing spondylitis (whites) 92%
Ankylosing spondylitis (African Americans) 50%
Reactive arthritis 60-80%
Psoriasis associated with spondylitis 60%
IBD associated with spondylitis 60%
Isolated acute anterior uveitis 50%
Undifferentiated spondyloarthropathy 20-25%
Table 2. Genetics of Ankylosing Spondylitis
Genes Chromosome Location Gene Product/Function
Definitely associated



HLA-B27



IL-1 gene cluster



CYP 2D6



ARTS1 (ERAP1)



IL23R



6p21.3



2q12.1



22q13.2



5q15



1p31.1



Antigen presentation



Modulator of inflammation



Metabolism of xenobiotics



ER aminopeptidase 1



IL-23 receptor



Possibly associated



ANKH



HLA-DRB1



5p15



6p21.3



Ectopic mineralization



Antigen presentation



Not associated



TGF-ß, MMP3, IL-10, IL-6, Ig allotypes, TCR, TLR4, NOD2/CARD15, CD14, NFßBIL1, PTPN22, etc



Multiple Multiple
Table 3. Diagnostic Criteria for Undifferentiated Spondyloarthropathy Using Modified Amor Criteria
Inclusion Criteria Exclusion Criteria
Inflammatory back pain 1 point Diagnosis of specific spondyloarthropathy
Unilateral buttock pain 1 point Sacroiliitis on radiograph = grade 2
Alternating buttock pain 2 points Precipitating genitourinary/gastrointestinal infection
Enthesitis 2 points Psoriasis
Peripheral arthritis 2 points Keratoderma blennorrhagicum
Dactylitis (sausage digit) 2 points Inflammatory bowel disease (Crohn disease or ulcerative colitis)
Acute anterior uveitis 2 points Positive rheumatoid factor
HLA-B27 –positive or family history of spondyloarthropathy 2 points Positive antinuclear antibody, titer > 1:80
Good response to nonsteroidal anti-inflammatory drugs 2 points  
Diagnosis of spondyloarthropathy with 6 or more points
Table 4. Clinical and Laboratory Features of Undifferentiated Spondyloarthropathy
Clinical or Laboratory Feature Frequency
Inflammatory back pain 90%
Buttock pain 80%
Enthesitis 75%
Peripheral arthritis 40%
Dactylitis (sausage digits) 20%
Acute anterior uveitis 1-2%
Fatigue 55%
Elevated ESR 32%
HLA-B27 –positive 25%
ESR = erythrocyte sedimentation rate.
Table 5. ESSG and Amor Criteria for Diagnosis of Spondyloarthropathy
ESSG Criteria Amor Criteria*
Inflammatory spinal pain or synovitis and one of the following: Inflammatory back pain 1 point
Alternating buttock pain Unilateral buttock pain 1 point
Enthesitis Alternating buttock pain 2 points
Sacroiliitis Enthesitis 2 points
IBD Peripheral arthritis 2 points
Positive family history of spondyloarthropathy Dactylitis (sausage digit) 2 points
  Acute anterior uveitis 2 points
  HLA-B27 –positive or family history of spondyloarthropathy 2 points
  Good response to NSAIDs 2 points
*Diagnosis of spondyloarthropathy with 6 or more points.



European Spondyloarthropathy Study Group (ESSG); IBD = inflammatory bowel disease; NSAID = nonsteroidal anti-inflammatory drug.



Table 6. New York and Rome Criteria for Diagnosis of Ankylosing Spondylitis
New York Criteria Rome Criteria
  • Low back pain with inflammatory characteristics
  • Limitation of lumbar spine motion in sagittal and frontal planes
  • Decreased chest expansion
  • Bilateral sacroiliitis grade 2 or higher
  • Unilateral sacroiliitis grade 3 or higher
  • Low back pain and stiffness for >3 months that is not relieved by rest
  • Pain and stiffness in the thoracic region
  • Limited motion in the lumbar spine
  • Limited chest expansion
  • History of uveitis
Definite ankylosing spondylitis when the fourth or fifth criterion mentioned presents with any clinical criteria Diagnosis of ankylosing spondylitis when any clinical criteria present with bilateral sacroiliitis grade 2 or higher
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.